Unknown OBSERVATIONAL NCT01652560

Observational Studies of the Application of Bevacizumab in HER2-negative Breast Cancer Neoadjuvant Chemotherapy (BIBC)

Sponsor: LiNanlin,Ph.D, Chief Physician,Clinical Professor

Conditions Bevacizumab Breast Cancer Molecular Targeted Therapy Neoadjuvant Chemotherapy

Interventions bevacizumab

Updated 7 times since 2017 Last updated: Jul 25, 2012 Started: Jun 30, 2012 Primary completion: Jun 30, 2014 Completion: Sep 30, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Bevacizumab and Breast Cancer, this trial is ongoing. The trial is conducted by LiNanlin,Ph.D, Chief Physician,Clinical Professor and has accumulated 7 data snapshots since 2012. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Unknown
Jul 2024 — Sep 2024 [monthly]

Unknown

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status
Sep 2020 — Jan 2021 [monthly]

Unknown Status
Jun 2018 — Sep 2020 [monthly]

Unknown Status

▶ Show 2 earlier versions

Apr 2018 — Jun 2018 [monthly]

Unknown Status

Phase: NA → None
Jan 2017 — Apr 2018 [monthly]

Unknown Status NA

First recorded

Jun 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

LiNanlin,Ph.D, Chief Physician,Clinical Professor
Roche Pharma AG

Data source: Xijing Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Xi'an, China